Deep Track Capital led a $126m Series B extension in Halda Therapeutics.

Deep Track Capital, an investment firm focused on the life sciences industry, led a $126m Series B extension in Halda Therapeutics, a biotechnology company developing cancer therapies, with participation from Frazier Life Sciences, RA Capital Management, Vida Ventures, Boxer Capital, Taiho Ventures, Canaan Partners, Access Biotechnology, Elm Street Ventures and Connecticut Innovations. “We are excited to have the support of this leading group of new healthcare investors who share our vision to be a cancer drug innovator. This financing will enable us to bring to patients our oral, selective, and widely applicable cancer cell-killing mechanism that is designed to overcome drug resistance, which is a major shortcoming of many current standard of care cancer treatments,” Kat Kayser-Bricker, Halda Therapeutics CSO.